

ASX Release

SUDA LTD ANNOUNCES SUCCESSFUL OUTREACH IN USA

PERTH, AUSTRALIA – 27 June 2014: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces progress with its business development activities following its successful outreach to prospective licensees, acquirers and collaborators at the BIO International Convention. This event was held in San Diego Convention on 23-26 June 2014.

The convention is the largest, most influential global industry conference, which attracts the biggest names in the pharmaceutical and biotech sector, offering key networking and partnering opportunities. SUDA met with more than 40 international pharmaceutical companies at this event.

The discussions with prospective partners spanned ArTiMist™, SUDA's antimalarial sublingual spray, and the Company's other advanced clinical-stage oral sprays, as well as the application of SUDA's OroMist drug delivery technology to new drugs. SUDA is creating competitive interest across several of its products, which the Company intends to leverage to optimise the financial terms of its anticipated licensing agreements and trade sales.

Commenting on SUDA's outreach in the USA, Mr Stephen Carter, Chief Executive Officer of SUDA said: "The interest in our pipeline and technology from US and international companies at the BIO 2014 convention exceeded our expectations. Many of these new prospective partners have already indicated a desire to advance to full due diligence and will thus have to compete with the pharmaceutical companies that have already advanced to this stage of deal making. I am delighted by the progress we are making towards our business development goals."



Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA LTD
Tel: +61 8 6142 5555
sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's most advanced product is a novel sub-lingual treatment, ArTiMist™, for severe malaria in children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other development stage products include orals sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting and erectile dysfunction. For more information, visit www.sudaltd.com.au